Evidence map›Paper›PMID 20676755›Full record

Trial reportBreast cancer research and treatment2011

Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study.

Theodore M Brasky, Matthew R Bonner, Kirsten B Moysich, Heather M Ochs-Balcom, Catalin Marian, Christine B Ambrosone, Jing Nie, Meng Hua Tao, Stephen B Edge, Maurizio Trevisan and 2 more

Abstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Breast cancer research and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Genetic Variants inFrontiers in oncology · 2021
    Article
  6. Association between ABCB1, ABCG2 carrier protein and COX-2 enzyme gene polymorphisms and breast cancer risk in a Turkish population.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020
    Article
  7. Article
  8. Review
  9. Article
  10. PharmGKB summary: ibuprofen pathways.Pharmacogenetics and genomics · 2015
    Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Theodore M BraskyDepartment of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA. tbrasky@fhcrc.org
Matthew R Bonner
Kirsten B Moysich
Heather M Ochs-Balcom
Catalin Marian
Christine B Ambrosone
Jing Nie
Meng Hua Tao
Stephen B Edge
Maurizio Trevisan
Peter G Shields
Jo L Freudenheim
University at Buffalo, State University of New York · USRoswell Park Comprehensive Cancer Center · USFred Hutch Cancer Center · USGeorgetown University · USGeorgetown University Medical Center · USNevada System of Higher Education · US

Funding

VITAMIN C (ASCORBATE) METABOLISM IN DROSPHILA MELANOGASTERP41RR013461 · NCRR · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · PI ALLEN, LINDSAY H · 1999 to 2011
$20.8M
Cancer Prevention Trng-Nutrition, Exercise &GeneticsR25CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI WHITE, EMILY · 2002 to 2016
$7.3M
Methylation and Oxidation in Breast Cancer EpidemiologyR01CA092040 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI FREUDENHEIM, JO L · 2002 to 2005
$2.5M
Estrogen Receptor 1 Gene, Adiposity, and Breast CancerK07CA136969 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI OCHS-BALCOM, HEATHER M · 2009 to 2013
$810k
Established Investigator Award Anti-Inflammatory Exposures in Cancer PreventionK05CA154337 · NCI · UNIVERSITY OF WASHINGTON · PI WHITE, EMILY · 2011 to 2015
$637k
PILOT--GEOGRAPHIC INFORMATION SYSTEM FOR ALCOHOL STUDIESP50AA009802 · NIAAA · RESEARCH INSTITUTE ON ADDICTIONS · PI RUSSELL, MARCIA · 1994 to 1998
–
NCI NIH HHS K05 CA154337NCI NIH HHS K05CA154337NCI NIH HHS K07 CA136969NCI NIH HHS R01 CA092040NCI NIH HHS R01CA92040NCI NIH HHS R25 CA094880NCI NIH HHS R25-CA94880NCRR NIH HHS P41 RR013461NIAAA NIH HHS P50 AA009802
6 · The paper itself

Abstract

Chronic inflammation has been consistently associated with cancers of several sites, including the breast, and inhibition of inflammation through the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been inversely associated with risk. As NSAIDs bind with cyclooxygenase-2 (COX-2), genetic variation in COX-2 may influence breast cancer risk by affecting inflammatory response and response to NSAID use. We identified eight single nucleotide polymorphisms (SNPs) for COX-2 and examined their association with risk of breast cancer in a population-based case-control study in Western New York. Cases had incident, first primary, histologically confirmed breast cancer (n = 1077). Controls (n = 1910) were randomly selected from NY Department of Motor Vehicles records (< 65) or Medicare rolls (≥ 65). Participants were queried on adult lifetime use of aspirin and recent use of ibuprofen. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). One SNP, rs2745559, was associated with an increased risk of breast cancer (OR 1.23, 95% CI 1.03-1.46). Associations with other variants were not evident. Significant interaction (P interaction = 0.04) between recent aspirin use and rs4648261 was also observed. Variation in COX-2 was modestly associated with breast cancer risk, indicating that COX-2 may play a role in breast carcinogenesis. Better understanding of the role of COX-2 genetic variation and interaction with NSAID use in breast carcinogenesis has potential to inform prevention strategies.

Indexed as

AdultAgedAnti-Inflammatory Agents, Non-SteroidalAspirinBreastBreast NeoplasmsCase-Control StudiesClinical Trials, Phase II as TopicCyclooxygenase 2DNA, NeoplasmFemaleHumansIbuprofenMiddle AgedPolymerase Chain ReactionPolymorphism, Single NucleotideAnti-Inflammatory Agents, Non-SteroidalAspirinCyclooxygenase 2DNA, NeoplasmIbuprofenPTGS2 protein, human

Identifiers

PMID20676755
PMCPMC2992094
OpenAlexW1973769396

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.